Form 4: Werewolf Therapeutics' Chief Medical Officer Randi Isaacs Reports Stock Option Grants

Randi Isaacs, Chief Medical Officer of Werewolf Therapeutics, reports the acquisition of stock options on January 2, 2025.

Summary

• Randi Isaacs, the Chief Medical Officer of Werewolf Therapeutics, Inc., filed a Form 4 on January 6, 2025.
• The filing reports the grant of two stock option tranches on January 2, 2025.
• One option grant is for 187,500 shares with a strike price of $1.56, vesting monthly over four years starting February 1, 2025, and expiring on December 31, 2034.
• The second option grant is for 68,151 shares with a strike price of $1.56, exercisable from January 2, 2027, vesting monthly over four years starting February 1, 2025, and expiring on December 31, 2034.
• Following the reported transactions, Isaacs directly owns options for 187,500 and 68,151 shares of Werewolf Therapeutics common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance. It aligns the executive's interests with those of the shareholders.

Positives

• The grant of stock options to the Chief Medical Officer aligns her interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Werewolf Therapeutics.
• Comparable companies such as Arcus Biosciences, Revolution Medicines, and Relay Therapeutics also utilize stock options to incentivize their leadership teams.
• The vesting schedules, typically spanning three to four years, are also in line with industry norms to ensure long-term commitment and alignment with shareholder value creation.

Stakeholder Impact

• Shareholders: The stock option grants align the executive's interests with increasing shareholder value.
• Employees: The grants can boost morale by demonstrating the company's commitment to its leadership.

Key Dates